| Jinbo Yang | Ph.D | Professor | Doctor Supervisor | ||||||||
Department | Innovation Center for Marine Drug Screening & Evaluation | |||||||||||
Office Phone | 0532-85906810 | Email: | yangjb@ouc.edu.cn yangjb@qnlm.ac | |||||||||
Address | Room C305, Marine Biomedical Research Institute, Fushan Campus, Ocean University of China | |||||||||||
Research Direction | 1.Cancer Biology, Tumor Immunology, Molecular Pharmacology 2.Cancer Signal Transduction Network, Tumor Immune Microenvironment and Omics Research 3.High-throughput Drug Screening and Intelligent Supercomputing Based Drug Screening | |||||||||||
Biography |
|
|
|
| ||||||||
Distinguished expert of "Taishan Scholar" in Shandong Province, chief professor and doctoral supervisor of " Blue Medicine Talent " of Ocean University of China; director of Innovation center for marine drug screening & evaluation of Qingdao National Laboratory of Marine Science and Technology. The research direction is cancer biology, tumor immunology and molecular pharmacology; focusing on the relationship and mechanism of caner signal transduction network regulation, tumor immune microenvironment and omics research, as well as high-throughput drug screening and intelligence supercomputer based virtual drug screening. Presided over a number of national natural projects, key projects of the Science and Technology Plan of the Ministry of Science and Technology, and major scientific and technological innovation projects in Shandong Province; as the corresponding author have published more than 30 papers in Cell Res, STTT, J Hepatology, PNAS, EMBO J, Science Advances, Cell Mol Immunol, etc., and obtained a number of authorized national invention patents. | ||||||||||||
Education |
|
|
|
| ||||||||
1996.09 - 2001.06 | Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences | Biochemistry and Molecular Biology | PhD | |||||||||
1987.09 - 1991.06 | Lanzhou University | Biochemistry | Bachelor | |||||||||
|
|
| ||||||||||
Work Experience |
|
|
|
| ||||||||
2022.05 - | Marine Biomedical Research Institute, Ocean University of China | Chief Professor of "Blue Medicine Talent" |
| |||||||||
2016.07 - | School of Medicine & Pharmacy, Ocean University of China | Professor, Doctoral Supervisor |
| |||||||||
2016.07 - 2022.04 | Qingdao Marine Biomedical Research Institute | PI, Chief Scientist |
| |||||||||
2016.09 - | Innovation center for marine drug screening & evaluation, Qingdao National Laboratory of Marine Science and Technology | Director |
| |||||||||
2007.07 - 2016.06 | School of Life Sciences, Lanzhou University | "Cuiying" Distinguished Professor, Doctoral Supervisor |
| |||||||||
2007.07 - 2016.06 | Institute of Cancer Biology and Drug Research, Lanzhou University | Director |
| |||||||||
2001.11 - 2015.12 | Cleveland Clinic | Postdoctoral Research Fellow, Associate Staff, Project Staff, Adjunct Staff, Staff |
| |||||||||
Academic Acitivities |
|
|
| |||||||||
Deputy Director of the Professional Committee of Marine Drug Pharmacology of the Chinese Pharmaceutical Association, Deputy Director of the Professional Committee of Intelligent Drugs of the Chinese Pharmaceutical Association, Vice Chairman of the Marine Biotechnology Branch of the China Ocean Development Research Association, Deputy Director of the Professional Committee of Marine Drugs of the Qingdao Pharmaceutical Association, Editor of the Chinese Journal of Biochemical Medicine Committee, International Marine Pharmaceuticals Website (marine pharmaceuticals website) Scientific Advisor Honor Award
7. Distinguished Expert of "Taishan Scholars" in Shandong Province, 2017 | ||||||||||||
Courses |
|
|
|
| ||||||||
Pharmacology (Undergraduate Course) Frontiers in Pharmacology (Graduate Program) Frontiers in Medicinal Chemistry (Graduate Program) | ||||||||||||
Research Interests |
|
|
|
| ||||||||
1.Caner signal transduction and tumor immunity The occurrence of tumors is related to many signaling pathways. The growth of tumor cells and their responsiveness to drug treatment depend not only on the gene mutations they carry, but also on many dynamic characteristics of the tumor microenvironment. In the tumor microenvironment, the ongoing crosstalk between tumor cells and stromal and immune cells further complicates signal transduction. Various immune cells contained in the tumor microenvironment are involved in maintaining a tumor-promoting immunosuppressive environment. Monocyte-derived or tissue-resident myeloid cells in the tumor microenvironment are extremely heterogeneous. The phenotypic heterogeneity and functional plasticity of macrophages are closely related to their polarization states, and macrophages in different polarization states have different gene expression profiles of cytokines/chemokines. Our research direction mainly focuses on the discovery and regulation of molecular events that play an important role in the polarization state of macrophages in the process of inflammatory response and tumor microenvironment, as well as drug screening and drug development based on immune targets, precision medicine and individualization medication evaluation. 2.JAK-STAT signal transduction pathways and gene regulation research Our research group discovered two new threonine phosphorylation sites (hSTAT2-T387, T404) on the STAT2 molecule, which play important functions in interferon-mediated antiviral and antitumor effects. Type I interferon (I-IFN) is widely used clinically to treat tumors and viral infections, but the regulation mechanism of its curative effect and drug resistance is still not very clear. STAT2-T387A and T404A mutations can respectively enhance and down-regulate the expression of I-IFN-induced downstream genes, and positively or negatively regulate I-IFN signaling. We will study in depth the mechanism of STAT2-T387 and T404 phosphorylation regulating I-IFN signaling pathway; identify phosphokinases that mediate STAT2-T387 and T404 phosphorylation and screen their inhibitors or activators; construct mouse mSTAT2-T386A and T403A Knock-in mice to explore the effects and mechanisms of mSTAT2-T386 and T403 phosphorylation on the regulation of I-IFN-mediated anti-virus, anti-infection, anti-tumor, cell development, and immune regulation. 3.High-throughput and supercomputing drug screening and druggability research High-throughput screening platform and efficacy evaluation system for anti-tumor drugs based on signaling pathways and molecular targets such as key tumor molecules JAK-STAT, NFkB, p53, Wnt, Notch, PD-1/PD-L1, and carry out drug screening and systematic pharmacology and pharmacodynamics research; for more than 40,000 marine natural products that have been reported and the constructed marine natural product three-dimensional structure database , establish a supercomputer virtual drug screening technology system and use it for marine innovative drug discovery and druggability research. 4.Multi-omics technology in the study of the targets and mechanism of marine natural products The backwardness of research methods and means on drug targets and mechanisms has greatly restricted the development process of marine-derived compounds. The targets and mechanisms of action are not clear, making it impossible to convert massively isolated natural products into drug leads with clear targets. We use transcriptomics, proteomics, metabolomics and other omics technologies, big data, protein expression and co-crystallization and other cell biology and molecular biology analysis methods to explore targets and mechanisms of marine natural products. Systematic and comprehensive research on the pharmacological effects of drugs on biological organisms, providing a standardized and streamlined research platform for the research on drug targets and mechanisms of action of marine-derived compounds. | ||||||||||||
Publications |
|
|
| |||||||||
Papers |
|
|
| |||||||||
1.Qiaoling Song, Shyamasree Datta, Xue Liang, Xiaohan Xu, Paul Pavici, Xiaonan Zhang, Yuanyuan Zhao, Shan Liu, Zhan Zhao, Chunhua Lin, Yuxin Wang, Peng Han, Peng Jiang, Yating Qin, Wei Li, Yingying Zhang, Yonglun Luo, Ganes Sen, George R. Stark, Chenyang Zhao*, Thomas Hamilton* & Jinbo Yang*. Type I Interferon Signaling Facilitates Resolution of Acute Liver Injury by Priming Macrophage Polarization. Cellular & Molecular Immunology . (2022); DOI:10.1038/s41423-022-00966-y. (IF 22.1) 2.Ruihua Liu, Yang Tian, Jie Wang, Zemin Wang, Xiangqian Li, Chenyang Zhao, Ruoyu Yao, Shuo Li, Leifeng Yuan, Jinbo Yang* & Dayong Shi*. Visible-light-initiated radical 1,3-difunctionalization of β,γ -unsaturated ketones. Science Advances. (2022); 8(49):eabq8596. (IF 15.0) 3.Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, Shan Liu, Tatsunori Miyata, Qiaoling Song, Qingda Wei, Chenyang Zhao, Chunhua Lin & Jinbo Yang*. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduction and Targeted Therapy. (2022); 7(1):287. (IF 38.1) 4.Wei Wei, Yazhuo Zhang, Qiaoling Song, Qianyue Zhang, Xiaonan Zhang, Xinning Liu, Zhihua Wu, Xiaohan Xu, Yuting Xu, Yu Yan, Chenyang Zhao* & Jinbo Yang*. Transmissible ER stress between macrophages and tumor cells configures tumor microenvironment. Cellular and Molecular Life Sciences. (2022); 79(8):403. (IF 9.3) 5.Zhan Zhao, Yazhuo Zhang, Danling Gao, Yidan Zhang, Wenwei Han, Ximing Xu, Qiaoling Song, Chenyang Zhao* & Jinbo Yang*. Inhibition of Histone H3 Lysine-27 Demethylase Activity Relieves Rheumatoid Arthritis Symptoms via Repression of IL6 Transcription in Macrophages. Front Immunol. (2022); 13:818070. (IF 8.8) 6.Yuxin Wang, Qiaoling Song, Wei Huang, Yuxi Lin, Xin Wang, Chenyao Wang, Belinda Willard, Chenyang Zhao, Jing Nan, Elise Holvey-Bates, Zhuoya Wang, Derek Taylor, Jinbo Yang* & George R. Stark*. A virus -induced conformational switch of STAT1-STAT2 dimers boosts antiviral defenses. Cell Research. (2021); 31(2):206-218. (IF 25.6) 7.Han Wang#, Hao Zhou#, Quanri Zhang, Kyle L. Poulsen, Vanessa Taylor, Megan R. McMullen, Doug Czarnecki, DhweejaDasarathy, Minjia Yu, Yun Liao, Daniela S. Allende, Xing Chen, Lingzi Hong, Junjie Zhao, Jinbo Yang*, Laura E. Nagy* & Xiaoxia Li*. Inhibition of IRAK4 kinase activity improves ethanol induced liver injury in mice. J. Hepatology. (2020); 73(6):1470-1481. (IF 25.1) 8.Ning Zhu, Jing Zhang, Yuping Du, Xiaodong Qin, Ruidong Miao, Jing Nan, Xing Chen, Jingjie Sun, Rui Zhao, Xinxin Zhang, Lei Shi, Xin Li, Yuxi Lin, Wei Wei, Aihong Mao, Zhao Zhang, George R. Stark*, Yuxin Wang* & Jinbo Yang*. Loss of ZIP Facilitates JAK2-STAT3 Activation in Tamoxifen-Resistant. Proc Natl Acad Sci USA. (2020); 117(26):15047-15054. (IF 11.2) 9.Jing Nan, Yuxn Wang, Jinbo Yang* & George R. Stark*. IRF9 and unphosphorylated STAT2 cooperate with NF-kB to drive IL-6 expression. Proc Natl Acad Sci USA. (2018); 115(15):3906-3911. (IF 9.4) 10.Yuxin Wang, Jing Nan, Belinda Willard, Xin Wang, Jinbo Yang* & George R. Stark*. Negative regulation of type I interferon signaling by phosphorylation of STAT2 on T387. EMBO J. (2017); 36(2):202-212. (IF 11.2) 11.Yuxin Wang, Anette H. H. van Boxel-Dezaire, HyeonJooCheon, Jinbo Yang* & George R. Stark*. STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. Proc Natl Acad Sci USA. (2013); 110(42):16975-80. (IF 9.8) 12.Jinbo Yang*, Jing Huang, Maupali Dasgupta, Nathan Sears, Masaru Miyagi, Benlian Wang, Mark R. Chance, Xing Chen, Yuping Du, Yuxin Wang, Lizhe An, Qin Wang, Tao Lu, Xiaodong Zhang, Zhenghe Wang & George R. Stark*. Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci U S A. (2010); 107(50):21499-504. (IF 9.8) 13.Jinbo Yang, Xudong Liao, Mukesh K. Agarwal, Laura Barnes, Philip E. Auron & George R. Stark*. Unphosphorylated STAT3, Increased by gp130-Linked Cytokines, Activates Transcription by Binding to NFB. Genes & Development. (2007); 21(11):1396-408. (IF 14.8) 14.Jinbo Yang, Moitreyee Chatterjee-Kishore, Susan M. Staugaitis, Hannah Nguyen, KarniSchlessinger, David E. Levy & George R. Stark*. Novel Roles of Unphosphorylated STAT3 in Oncogenesis and Transcriptional Regulation. Cancer Research. (2005); 65: (3):939-47. (IF 7.6) 15.Jin-Bo Yang, Zhi-Jun Duan, Wei Yao, Onel Lee, Li Yang, Xin-Ying Yang, Xia Sun, Catherine CY Chang, Ta-Yuan Chang & Bo-Liang Li*. Synergistic transcriptional activation of human ACAT-1 gene by IFN- and ATRA in THP-1 cells. J. Biol. Chem. (2001); 276 (24):20989-98. (IF 7.3) | ||||||||||||
Books |
|
|
|
| ||||||||
| ||||||||||||
|
|
|
|
| ||||||||
Projects | ||||||||||||
National level: 1.The National Health and Medical Commission's "Major New Drug Creation" Science and Technology Major Project - Marine Biological Source Compound Library Construction Project. Project number: 2018ZX09735004, 2018.01 - 2021.12, 4.56 million. PI 2.The key project of "International Science and Technology Cooperation" of the Ministry of Science and Technology, "High-throughput screening and mechanism research of anti-tumor and anti-atherosclerotic drugs of traditional Chinese medicine". Project number: 2009DFA30990. 2009.01 - 2012.12, 1.78 million yuan. PI 3.General project of the National Foundation of China, "Research on the key role and mechanism of ZIP in the growth and drug resistance of breast cancer cells". Project number: 31571439. 2016.01 - 2019.12, 650,000 yuan. PI 4.General project of the National Foundation of China, "Application of a new type of insertion mutation technology in the search for regulators of orphan nuclear receptor ROR-alpha". Project number: 30970606. 2010.01 - 2012.12, 300,000 yuan. PI Provincial: 1.Major new drug creation in Shandong Province - "China Blue Drug Bank - Marine Innovative Drug System Preclinical Research and Drug Development". Project number: 2020CXGC010503, 2021.01 - 2023.12, 8.15 million. PI 2.Shandong Province's major scientific and technological innovation project, "China's blue drug library - the construction of a marine drug screening technology system based on intelligent supercomputing". Project number: 2018SDKJ0402. 2018.09 - 2021.12, 8 million. PI 3.Shandong Peninsula National Independent Innovation Demonstration Zone "Blue Huizhi Double Hundred Talents" project. Project number: 2018-121. 2019.01 - 2020.12, 400,000. PI 4.Key project of Gansu Province International Science and Technology Cooperation Program, "High-throughput screening of active ingredients and chemical drugs of anti-tumor and anti-atherosclerotic traditional Chinese medicine". Project number: "0708WCGA149". 2008.01 - 2009.12, 100,000 yuan. PI 5.The Ministry of Education's " New Century Talents " support plan project, "Research on the Importance of Protein Methylation and Acetylation to the Function of STAT3". Project number: NCET-08-0260. 2009.01 - 2010.12, 500,000 yuan. PI Municipal and others: 1.Qingdao Innovation Leading Talent Project, "High-throughput screening and molecular mechanism research of anti-tumor targeted drugs". Project number: 16-8-3-11-zhc. 2017.01 - 2019.12, 1 million yuan. PI 2."Aoshan Talents" Outstanding Scientist Special Project of Qingdao National Laboratory of Marine Science and Technology, "Marine Drug Discovery and Drugability Research Based on Intelligent Supercomputing". Project number: 2017ASTCP-OS11. 2017.07 - 2021.12, 2.4 million. PI 3."China Blue Pharmacy" key technology pre-research project of Qingdao National Laboratory of Marine Science and Technology. Project number: 2016ASKJ08. 2017.01 - 2018.12, 3.89 million yuan. PI 4.Ocean University of China "Zhufeng" talent project, "Marine drug screening and druggability research based on key targets of major diseases". Project number: 201712013. 2016.07 - 2021.06, 3 million yuan. PI 5.Lanzhou University Cuiying talent construction project, "Anti-tumor drug screening and druggability research". Project number: 225-581602. 2007.07 - 2010.06, 2.5 million yuan. PI | ||||||||||||
| ||||||||||||
【Close】
